Honeybees are vital to global food security, yet colony collapse threatens ecosystems and agriculture worldwide. Discover ...
Clinical Trials Arena on MSN
Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial
Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled reductions in visceral fat, total fat ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity ...
Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...
Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) ...
Considerable on MSN
Arrowhead claims strong weight-loss boost
Arrowhead Pharmaceuticals said Tuesday that its gene-silencing drug candidate nearly doubled four-month weight loss ...
The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...
Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback